Data Entry Maintenance

Metadata Commons Identifier

HMC000044

Project Title

Validation of cured heart failure biomarkers

Project Description

<p><span style="color: rgb(38, 38, 38); font-family: system-ui, -apple-system, 'system-ui', 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Fira Sans', 'Droid Sans', 'Helvetica Neue', sans-serif; font-size: 14px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">While some patients appear to recover from the symptomatic phase of heart failure, their treatment is continued. This is due to the fact that currently there are no guidelines for assessing if a patient is cured of the heart failure. Without proper guidelines, clinicians are obligated to continue the standard heart failure treatment in order to avoid a relapse from deteriorating cardiac function. The biomarkers of cured heart failure could help physicians tailor the treatment decision, which could save cost over time and could reduce side effects and complications. The PROOF Centre team identified biomarkers of cured heart failure using data from transplant patients. The patients were enrolled as part of the Biomarkers in Transplantation study. Whole blood and plasma samples were used for Affymetrix microarray and iTRAQ proteomics analysis respectively. Organ failure biomarkers were discovered using the samples collected pre-transplant. The expression of these markers were monitored in the time course samples were collected from patients with stable graft function within the first year post-transplant. The biomarkers of cured heart failure were developed based on those genes/proteins that normalized after transplantation in the stable patients. To test the biomarker signatures usefulness, validations study was performed in subjects who either have recovered (case cohort) or have not yet recovered from organ failure (control cohort) using therapies that are not transplant-related. The objective of the program is to validate the biomarkers of cured heart failure discovered in the transplant patient data set in the patients from the Maintenance Clinic with stable heart function and from the Heart Failure Clinic with unstable heart function.</span></p>

Project Funder(s)

Canadian Institutes of Health Research (CIHR), PROOF Centre of Excellence

Project Institution(s)

University of British Columbia

Project Investigator(s)

Bruce McManus, Raymond Ng, Andrew Ignaszewski, Zsuzsanna Hollander

Data Access Request URL*

Keywords

proteomics, microarrays, biomarkers, heart failure, diagnosis, heart function recovery

Publication Link

https://pubmed.ncbi.nlm.nih.gov/24574204/

Study Completed

Cohort Name

Recovered heart function

Cohort Size

Disease/Condition Studied

heart transplant, heart disease, end-stage organ failure

Enrollment Time Window

2010-2011

Biobanking Consent Available

Medical History Available

Ethnicity Availability

Time Course

Patient Phenotypes

heart function recovery

Patient Outcomes

recovered

Clinical Data Types Available

demographics, cardiac function, comorbidities

Time Course Data Points

Enrollment City

Groups

Project

Cohort

Enrollment City

Groups

Samples and Omics